Tuesday, October 23, 2018
- 9:00AM-11:00AM
-
Abstract Number: 2100
Topical Endocannabinoid Administration Protects MRL-Lpr/Lpr Mice from Cutaneous Lupus Erythematosus
Systemic Lupus Erythematosus – Animal Models Poster- 9:00AM-11:00AM
-
Abstract Number: 2719
Tracking the Risk of Infections in ANCA-Associated Vasculitis: Results from a Scottish Matched-Cohort Study
Vasculitis – ANCA-Associated Poster II- 9:00AM-11:00AM
-
Abstract Number: 1977
Transcriptional Perturbation of RA-Risk Enhancer By CRISPR-DEADCAS9 Regulates LONG Range GENE Targets
Genetics, Genomics and Proteomics Poster- 9:00AM-11:00AM
-
Abstract Number: 1966
Transcriptome and Methylome Integrative Molecular Analysis Uncovers a New Systemic Autoimmune Disease Classification
Genetics, Genomics and Proteomics Poster- 9:00AM-11:00AM
-
Abstract Number: 2280
Transcriptomic Analysis of Hidradenitis Suppurativa Skin Demonstrates Dysregulation of Antimicrobial Proteins and Inflammatory Pathways
Miscellaneous Rheumatic and Inflammatory Diseases Poster III: Sarcoid, Inflammatory Eye Disease, and Autoinflammatory Disease- 9:00AM-11:00AM
-
Abstract Number: 2076
Transmembrane TNF (tmTNF) Transgenic Mice Exhibit Enlarged Lymph Nodes and Elevated Numbers of High Endothelial Cells Associated with Increased Lymphocyte Recruitment
Spondyloarthritis Including Psoriatic Arthritis – Basic Science Poster- 9:00AM-11:00AM
-
Abstract Number: 2491
Treat-to-Target (T2T) Is Not Enough: Identify Factors Leading to a Mismatch between T2T and HAQ Among RA Patients through Data Mining from Smart System of Disease Management (SSDM)
Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster III: Complications of Therapy, Outcomes, and Measures- 9:00AM-11:00AM
-
Abstract Number: 2281
Treatment Choices and Response Rates of SAPHO Syndrome: Single Center Case Series
Miscellaneous Rheumatic and Inflammatory Diseases Poster III: Sarcoid, Inflammatory Eye Disease, and Autoinflammatory Disease- 9:00AM-11:00AM
-
Abstract Number: 2512
Treatment Continuation on the Etanercept Original in Comparison with a Biosimilar
Rheumatoid Arthritis – Treatments Poster III: Biosimilars and New Compounds- 9:00AM-11:00AM
-
Abstract Number: 2344
Treatment Modes in Rheumatoid Arthritis: Moving Toward Shared Decision-Making
Patient Outcomes, Preferences, and Attitudes Poster II: Patient Perspectives- 9:00AM-11:00AM
-
Abstract Number: 2270
Treatment of Refractory Cystoid Macular Edema to Conventional Immunosuppressive Therapy: Tocilizumab Vs Anti-TNF-Alpha. Multicenter Study of 59 Patients
Miscellaneous Rheumatic and Inflammatory Diseases Poster III: Sarcoid, Inflammatory Eye Disease, and Autoinflammatory Disease- 9:00AM-11:00AM
-
Abstract Number: 2166
Treatment of Venous Thrombotic Events in Behçet Disease: A Systematic Literature Review
Epidemiology and Public Health Poster III: SLE, SSc, APS, PsA, and Other Rheumatic Diseases- 9:00AM-11:00AM
-
Abstract Number: 2665
Treatment Trends of Systemic Lupus Erythematosus during Early-Years of the Disease
Systemic Lupus Erythematosus – Clinical Poster III: Treatment- 9:00AM-11:00AM
-
Abstract Number: 2774
Treatment with Methotrexate and Risk of Ischemic Relapses in Patients with Giant Cell Arteritis in Clinical Practice
Vasculitis Poster III: Immunosuppressive Therapy in Giant Cell Arteritis and Polymyalgia Rheumatica- 9:00AM-11:00AM
-
Abstract Number: L05
Treatment-Naïve, Early Rheumatoid Arthritis Patients Demonstrate Reversible Abnormalities of Vascular Function on Cardiac MRI with RA Therapy with Preliminary Suggestion of Greater Improvement with Anti-TNF Compared to MTX/Conventional Therapy – a First, RCT Derived Longitudinal Study